Shots:

• The P-III PSOARING 3 is an OLE study assessing Tapinarof (1%) in patients with plaque psoriasis for ~40wks. and a 4wks. safety follow-up period
• The interim analyses showed 57.3% of study participants who entered the study with a PGA of ≥ 2 achieved a PGA of 0 or 1 while 39.2% achieved PGA 0 and the results were consistent with the previous studies. The findings will be included in NDA submission expected in mid-2021 and completion of PSOARING 3 study in H1’21
• In an integrated analysis- 63.5% & 44.2% of subjects achieved PASI7 & 90 with the improvement in treatment effect beyond 12wks. Remittive effect of ~4mos. following treatment- discontinuation was observed

 ­ Ref: Dermavant | Image: Business Wire